Merck just announced it’s carving out its cancer business into a separate unit, and honestly this feels like a pretty smart move. Oncology is already the crown jewel for $MRK, and giving it its own structure could mean faster decisions, cleaner reporting, and more focus on growth instead of being buried inside a massive pharma org. From an investor angle, this looks like a classic unlock value play. If the cancer unit starts moving quicker on R&D, partnerships, or even future spinoff potential, that could be a long term win. On the flip side, it also puts pressure on the rest of the business to perform without leaning so hard on oncology results. I’m curious how the market prices this in. Do you see this as $MRK sharpening its edge, or is it just corporate reshuffling with limited upside?